Regeneron Pharmaceuticals Inc. (REGN)

Inventories are stated at the lower of cost or estimated realizable value. Regeneron determines the cost of inventory using the first-in, first-out, or FIFO, method.

Regeneron capitalizes inventory costs associated with Regeneron’s products prior to regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval.

Regeneron periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate. In addition, Regeneron’s products are subject to strict quality control and monitoring which Regeneron performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, Regeneron records a charge to write down such unmarketable inventory to its estimated realizable value.

Source: 10-K (filing date: 2019-02-07).

Regeneron Pharmaceuticals Inc., balance sheet: inventory

US$ in thousands

		Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Raw materials
	Work-in-process
	Finished goods
	Deferred costs
	Inventories

Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).